SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Alan Turing — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAlan Turing
Date of birth1912-06-23
IdentifiersMRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290
Document date1953-06-09
AuthorRupert Hallam, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week review of hormone recovery and depression treatment. [S]

History of Present Illness

Mr. Turing returns eight weeks after his first visit, about eleven weeks after the last estrogen injection. The breast tenderness is less and he no longer notices it when running. Morning erections returned three weeks ago and his libido is coming back. He has had seven psychotherapy sessions and runs about 25 km a week. His mood is somewhat better, but he still feels flat most days, has little pleasure outside work, and wakes early. He has had no suicidal thoughts. After the last visit he asked to think about medicine; today, after a discussion of sertraline, mirtazapine, and bupropion and their effects on sexual function, weight, sleep, and blood pressure, he chose bupropion. He has no history of seizures, head injury, or an eating disorder and drinks little alcohol. [S]

ElementDetail
BreastsLess tender; no discharge
Sexual functionMorning erections back for three weeks; libido returning
PsychotherapySeven sessions
RunningAbout 25 km a week
SafetyNo suicidal thoughts
PHQ-912, down from 15

Review of Systems

SystemResultFinding
BreastPositiveMild tenderness on pressure only; no discharge
GenitourinaryNegativeErections returning; no testicular symptoms
NeurologicalNegativeNo seizures, fainting, or head injury ever
PsychiatricPositiveFlat mood and early waking; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1953-04-14activeS
Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route1953-06-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-06-09Body height178cmS
1953-06-09Body weight70.1kgS
1953-06-09Body mass index (BMI) [Ratio]22.1kg/m2S
1953-06-09Systolic blood pressure118mm[Hg]S
1953-06-09Diastolic blood pressure74mm[Hg]S
1953-06-09Heart rate58/minS
1953-06-09Respiratory rate14/minS
1953-06-09Body temperature36.6CelS
1953-06-09Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-06-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S
1953-06-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1953-06-09Testosterone [Mass/volume] in Serum or Plasma238ng/dL264-916 ng/dLLowS
1953-06-09Estradiol (E2) [Mass/volume] in Serum or Plasma26pg/mL7.6-42.6 pg/mLNormalS
1953-06-09Lutropin [Units/volume] in Serum or Plasma2.4m[IU]/mL1.7-8.6 m[IU]/mLNormalS
1953-06-09Follitropin [Units/volume] in Serum or Plasma3.1m[IU]/mL1.5-12.4 m[IU]/mLNormalS
1953-06-09Prolactin [Mass/volume] in Serum or Plasma12.4ng/mL4-15.2 ng/mLNormalS
1953-06-09Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS

Physical Exam

Vital signs recorded on 1953-06-09; see the Vital Signs section. [S]

SystemFinding
GeneralLean; more animated than at intake
BreastExamined with his agreement: glandular tissue about 3 cm behind each nipple, softer and only mildly tender; no discrete mass, skin change, discharge, or nodes
Mental statusAlert; mood "better, but grey"; affect mildly constricted and reactive; thought process linear; no suicidal ideation; insight and judgment good

Problems

ProblemClinical statusVerificationCodeProvenance
Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatmentactiveconfirmed N62S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic.
Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigueactiveconfirmed E23.1S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops.
Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonmentactiveconfirmed T38.5X5AS — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm.
Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime)activeconfirmed F32.1S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R).
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding of the bone-health workup.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBreast examination for size, tenderness, and any discrete massEvery visit until the gynecomastia settlesCompleted todayGlandular tissue about 3 cm behind each nipple, softer, mildly tender; no discrete mass
LaboratoryTestosterone, estradiol, LH, and FSHEvery 6 to 8 weeks after the exposure stops, until normalCompleted todayTestosterone 238 ng/dL (low, rising); estradiol 26 pg/mL; LH 2.4 and FSH 3.1 mIU/mL, now in range
LaboratoryProlactin after the estrogen clearsRepeat once after a raised valueCompleted today12.4 ng/mL, normal, down from 21.6; the rise was estrogen-related
LaboratoryHemoglobin while testosterone is lowWith each hormone check until normalCompleted today13.6 g/dL, back in range
Medication safetyTestosterone therapyOnly for persistent, symptomatic, confirmed testosterone deficiencyNot indicatedNot given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today12, down 20 percent from 15: partial response; bupropion added. Six weeks since the last score, two weeks beyond the monthly interval, because this review was timed to the hormone tests; no harm, as he had weekly therapy sessions and no suicidal thoughts
SurveyGAD-7With the PHQ-9 when anxiety symptoms were present at baselineCompleted today6, down from 8
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors unchanged; safety plan reviewed
SurveyBipolar screen before starting an antidepressantAt the initial workup; repeat if hypomanic features emergeCompleted todayStill no history of elevated mood, reduced need for sleep, or racing thoughts
Medication safetyAntidepressant tolerability check two weeks after starting2 weeks after starting and after each dose changeDueNurse telephone check booked for two weeks from today
Self-managementPsychotherapy, sleep, running, and social contactEvery visit during active treatmentCompleted todaySeven sessions; running about 25 km a week; early waking
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedNot on any of these drugs

Goal progress:

Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse telephone check in two weeks; review in eight weeks with hormone tests and PHQ-9. Next scheduled visit 1953-08-04: sixteen-week review of hormone recovery and depression treatment. [S]